23 Jul, 2026
According to Straits Research the global point of care diagnostics market was valued at $50.17 billion in 2025 and is anticipated to grow from $53.51 billion in 2026 to $89.7 billion by 2034, registering a CAGR of 6.67% during the forecast period 2026–2034.
Point-of-Care diagnostics are techniques used for the early and rapid diagnosis of disease. These techniques are susceptible and cost-effective and are applied in hospitals, clinics, ambulatory care, home healthcare, and research laboratories. The increasing prevalence of target illnesses is the most important factor driving market expansion. Point of care treatment permits speedy and dependable diagnostic testing with instantaneous results, enabling physicians/patients to make care-related decisions remotely and immediately.
The growing significance of point-of-care diagnostics in environmental monitoring and public health necessitates the development of technologies that simplify networking, making it more comfortable for medical practitioners to interpret test findings appropriately. Point-of-care tests can significantly improve the management of infectious diseases, especially in developing countries where timely access to healthcare can be challenging and when the healthcare system is underdeveloped and underfunded. In East and Southern Africa in 2021, UNAIDS estimated approximately 21.2 million HIV-positive individuals. Twenty thousand newly diagnosed cases of HIV were tallied throughout the Middle East and North Africa. It is anticipated that the demand for diagnostics that can be completed at the point of care will rise, accelerating the process of treating HIV infection.
The application of digital technology is projected to substantially impact the creation of POC solutions in settings with limited resources. As part of their go-to-market strategy, businesses in the POCT sector should place the utmost importance on expanding their use of telehealth as the industry standard. It is anticipated that the emergence of remote patient monitoring systems such as PixCell Medical, point-of-care technology for CBC testing, would benefit the market's development.
North America maintained the largest revenue share in the global point of care diagnostics market due to the rapidly increasing number of COVID-19 cases and critical players in both the United States and Canada. For example, in March 2022, the company bioLytical Laboratories Inc., situated in Canada, was awarded CE marking for the iStatis COVID-19 Antigen Home Test.
sales@straitsresearch.com